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CC BY-NC-ND license (http://creativeAbstract Since the identification of matrix metalloproteinases (MMPs), a family of zinc-
dependent endopeptidases, as being a driving factor for cancer progression and patient prog-
nosis, MMPs have been studied extensively. Although early programs targeting MMPs were
largely unsuccessful in clinical trials, they remain a viable and highly desirable therapeutic
target based on preclinical studies and their role in disease progression. As information
regarding the structure and function of these proteinases is compiled and biotechnology
evolves, tools to develop better inhibitors are within our grasp. Improved methods for high
throughput screening and in silico drug design programs have identified compounds which
are highly potent, have high binding affinities, and exhibit favorable pharmacokinetic profiles.
More recently, advances in drug delivery methods or compounds which bind outside the active
site have brought new light to the field. In this review, we highlight the role of MMPs in cancer,
clinical trials for MMP inhibitors, and novel approaches to targeting MMPs in cancer.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction to MMPs in cancer
Matrix metalloproteinases, or MMPs, are responsible for
remodeling the extracellular matrix (ECM). Such remodel-
ing processes are necessary for a vast and varied array of
physiological events, such as wound repair, organismalokmedicine.edu (J. Cao).
ity of Chongqing Medical
014.12.002
ng Medical University. Production
commons.org/licenses/by-nc-nd/growth and development, and mediation of immune re-
sponses. However, dysregulation of MMPs has been
observed in an equally diverse index of diseases. From
pulmonary disorders to autoimmune diseases to cancer (the
focus of this review), MMPs have been found to directly
contribute to disease progression.1e4
Cancer research has traditionally focused largely on
cancer cell mutations that confer either proliferative or
survival advantages. The tumor microenvironment, partic-
ularly the extracellular matrix, is now emerging as a key
player in influencing cancer progression. MMPs are present in
nearly all human cancers; they can be expressed by healthyand hosting by Elsevier B.V. This is an open access article under the
4.0/).
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blasts, and/or by non-fibroblastic cancer cells. This is of
great significance, as MMPs can influence the tumor envi-
ronment by promoting angiogenesis, tumor growth, and
metastasis.5,6 Accordingly, MMP expression is tied to tumor
aggressiveness, stage, and patient prognosis.7,8
Transcription of MMPs is tightly regulated and expression
is generally very low. Further regulation of MMP activity
occurs by post-translational modification, production of the
enzymes as zymogens requiring activation, and co-
expression of tissue inhibitors of metalloproteinases
(TIMPs).9,10 Dysregulation of any of these regulatory
mechanisms during pathological conditions may contribute
to worsening of disease.9
Increased expression of MMPs is correlated to increased
cancer cell proliferation and an increase in tumor size.
Overexpression of MMP-3 in the phenotypically normal
murine mammary epithelial cell line, SCp2, using a tetra-
cycline inducible system injected into surgically cleared
mammary tissue has been shown to be sufficient to induce
spontaneous disease progression.11 Similarly, MMP-2 levels
detected in cancer tissue are significantly correlated to
larger tumor size.12 Several MMPs have been shown to drive
cell migration and invasion through the basement mem-
brane. Sequence-specific silencing of MMP-14 alone signifi-
cantly attenuates both migration and invasion of cancer
cells in vitro.13 Similarly, silencing of MMP-9 decreases the
ability of glioma cells to migrate or invade.14 Further, the
number of metastatic lesions observed in xenografts of
MMP-9 knockdown triple negative breast cancer cells was
significantly fewer than in xenografts of cells transduced
with a non-target lentivirus.15 In a mouse xenograft model
of melanoma, increased levels of MMP-2 correlated to a
more malignant phenotype.16 Finally, MMPs have been
shown to contribute to angiogenesis by degrading basement
membranes, allowing for endothelial cell invasion. They
also cleave factors that increase or maintain the angiogenic
phenotype.17 Nearly every member of the MMP family has
been found to be dysregulated in human cancers, with
MMP-1,-2,-7,-9,-13, and -14 at the top of this list. Together,
these factors all point to MMPs as attractive targets for
therapeutics.
MMP substrate specificity
MMPs are calcium-dependent endopeptidases which require
coordination of a zinc ion to mediate catalysis. As implied
by their name, substrates of MMPs span a vast assortment
of extracellular components and the enzyme substrateTable 1 Substrate specificities of matrix metalloproteinases.
Group MMP Major
Collagenases MMP-1, MMP-8, MMP-13, MMP-18 Fibrill
Gelatinases MMP-2, MMP-9 Gelati
galect
Stromelysins MMP-3, MMP-10, MMP-11, MMP-12 Proteo
III, IV,
Matrilysins MMP-7, MMP-26 Fibron
Membrane-type MMP-14, MMP-15, MMP-16, MMP-25 Largepreferences have been used to classify this family into sub-
groups (Table 1). True collagenases are those MMPs which
can cleave the major fibrillar collagens (types I, II, and III)
at a precise site in the triple helical structure to produce 3/4
and 1/4 segments.
9 Gelatinases proteolyse denatured
collagen, also known as gelatin. They also cleave bioactive
signaling molecules, including chemokines, as well as acti-
vate certain other MMPs. Substrates of stromelysins are
among the most diverse, including proteoglycans, fibro-
nectin, laminin, casein, gelatin, types III, IV, IX and X
collagen. This subgroup also has the capacity to activate
certain other MMPs. While the previous groups are all
secreted proteases, matrilysins are an interesting group as
they can act either be secreted or act intracellularly. When
active within the cytoplasm of a cell, they are involved in
maintenance of the innate immune system by activating
defensin, a peptide with antibacterial functions.18 Their
extracellular functions involve mediation of cell-adhesion
(by degrading VE-cadherin) and hydrolysis of certain ma-
trix components, including fibronectin, type IV collagen,
and proteoglycans.19
The final major group of MMPs encompasses those which
are localized at the extracellular side of cell membranes.
Substrates of these MMPs include collagen as well as other
cell surface molecules and some bioactive molecules.20
Because of their localization to the cell surface, these
MMPs are also involved in processes and signaling pathways
allowing for angiogenesis, cell migration and invasion, and
other cellular functions such as proliferation, apoptosis,
and differentiation.21
Owing largely to their vast substrate diversity, MMPs
participate in nearly every biological process which involves
remodeling of the ECM, from implantation of an embryo
into the uterine wall22 to tissue necrosis. It comes as no
surprise then that altered expression or activity levels of
MMPs is associated with an expansive and extensive array of
pathologies.23
Several MMPs have been identified which fall outside of
the above described classification system. These “other”
MMPs include several isoforms expressed in non-primates of
which little is known about substrate preference.
MMP structure
As more MMP family members continue to be discovered
and the breadth of substrates is elucidated, a new para-
digm for classifying MMPs has emerged which groups the
proteases based on structural similarity. In this approach,
the known 23 paralogs of vertebrate MMPs are split intoECM substrates
ar collagens types I, II, III, VII, VIII and X, gelatin, aggrecan
n, collagen types IV, V, VII, X, and XIV, gelatin, elastin,
in-3, aggrecan, fibronectin
glycans, fibronectin, laminin, casein, gelatin, collagen types
IX and X
ectin, laminin, type IV collagen, proteoglycans, VE-cadherin
tenascin-C, fibronectin, laminin
28 J. Cathcart et al.eight groups, five of which represent the secreted MMPs and
three of which encompass the membrane-type MMPs
(Fig. 1).24,25 Nearly all MMPs share certain structural ele-
ments; these include an N-terminal signaling sequence
which dictates the localization of each MMP, a propeptide
region, a calcium-dependent active site which coordinates
a catalytic zinc ion, a linker region of varying length, and a
hemopexin-like domain. The exceptions to this general-
ization are MMP-7 and -23 which both lack the linker and
hemopexin domains. The catalytic domains of MMPs are
highly similar; they are all roughly spherical with a diam-
eter of approximately 40 A˚. Catalytic domains of MMPs are
described as shallow, intermediate, or deep. The active-
site cleft also harbors a hydrophobic S10-pocket which is
the primary determinant of substrate specificity.9 Aside
from the catalytic zinc ion required for proteolysis, a
structural zinc and at least one structural calcium ion can
be found within the active sites of all MMPs. Sequence an-
alyses indicate that the hemopexin-like domains, which
confer substrate specificity or mediate protein-protein in-
teractions, are the least homologous domains.24
Certain MMPs are distinguished from the others based on
the presence of additional domains; these may include a
fibronectin-like domain, which contains three repeats ofMinimal domain MMPs
(MMP-7,-26)
Simple hemopexin domain-
containing MMPs 
(MMP-1,-8,-13,-3,-10,-12,-19,
-20,-22)
Gelatin-binding MMPs
(MMP-2,-9)
Furin-activated secreted 
MMPs
(MMP-11,28)
Transmenbrane MMPs
(MMP-14,-15)
GPI-anchored MMPs
(MMP-17,25)
Vitronectin-like insert MMPs
(MMP-21)
Cys/Pro-Rich/IgG-like MMPs
(MMP-23)
Figure 1 Domain stfibronectin type II motifs to which gelatin and type IV
collagen substrates bind,26 a cysteine/proline-rich immu-
noglobulin-like domain,20,27 or a vitronectin-like domain
which has tandem repeats of a motif similar to that of the
cell adhesion protein.28 Further diversifying the family is the
fact that several MMPs are localized to the extracellular side
of a cell’s lipid bilayer. MMP-14, -15, -16, (also referred to as
membrane type I MMP, or MT-1, MT-2, and MT-3, respec-
tively) and MMP-24 are anchored to the membrane through
their transmembrane domain and contain a short carboxy-
terminal cytoplasmic domain. MMP-17 and MMP-25 are
tethered to the membrane by their glyco-
phosphatidylinositol (GPI) anchor.20,24,29
MMPs are usually secreted as zymogens and require
activation via proteolysis. The propeptide domain is a crit-
ical regulator of MMP activity by simply blocking access to
the catalytic domain. The propeptide domain is composed of
three alpha chains with flexible connecting loops which
interact with each other in order to form a hydrophobic
core.20,30,31 The prodomain of all MMPs is characterized by
inclusion of the common “structural signature” amino acid
sequence PRCGXPD which keeps the MMP inactive by a
cysteine switch mechanism.32,33 The sulfyhydryl group of
the cysteine in this sequence of the prodomain occupies theructures of MMPs.
Revisiting MMPs as therapeutic targets in cancer 29catalytic zinc ion and prevents a water molecule necessary
for proteolysis from accessing and interacting with the ion.34The early inhibitor programs
Traditional research on cancer drugs has focused almost
solely on compounds which kill cancer cells. However, most
forms of aggressive cancers remain resistant to these che-
motherapeutics and metastasis remains responsible for 90%
of patient deaths.35 In the early 1990’s, with the identifi-
cation of MMPs as contributing to cancer stage and patient
prognosis, nearly every pharmaceutical company began
heavily investing in a MMP inhibitor (MMPI) program. Opti-
mism was high that these drugs would represent a turning
point for cancer therapy.
As most enzyme-targeting drugs do, early inhibitors
targeting MMP activity were designed to bind within the
catalytic domain of these proteases. The initial therapeu-
tics were peptidomimetics, or compounds derived from the
sequences of the amino acids of the MMP’s endogenous li-
gands. Optimization to the backbone of these residues
yields compounds which tightly bind the active site but for
which the sisisile bond cannot be hydrolyzed. Importantly,
these compounds chelate the catalytic zinc ion in order to
render the protease inactive.36e38 The first peptidomi-
metics designed utilized a hydroxamic acid moiety to
chelate the zinc and bound with nanomolar affinity. These
compounds were designed around the glycine-leucine
cleavage site in collagen that can be cleaved by MMP-1,-8,
and -13.39
Batimastat, a broad-spectrum, competitive peptidomi-
metic is an injectable drug and the first MMPI to be tested
clinically (see Table 2 for a summary of clinically tested
MMPIs). Endpoints of these trials included investigation of
the drug’s ability to attenuate tumor invasion, angiogen-
esis, and migration.40 Although highly potent against MMP-
1,-2,-3,-7,-9 and -14 and effective in clinical trials for
malignant ascites and malignant pleural effusion, trials
were stopped during phase III. Due to its poor solubility and
very low oral bioavailability, the program was cancelled inTable 2 Clinically tested MMP inhibitors.
Inhibitor Class Selectivity Indication
Batimastat Peptidomimetic Broad spectrum Malignant a
Marimastat Peptidomimetic Broad spectrum Breast canc
non-small c
CGS 27023A Small molecule Broad spectrum Advanced so
Prinomastat Small molecule Broad spectrum Non-small c
multiforme,
Tanomastat Small molecule MMP-2, MMP-3,
MMP-9
Ovarian can
pancreas, n
rheumatoid
transplant
Doxycycline Tetracycline
derivative
Broad spectrum Approved fo
sclerosis (ph
aortic aneu
disease (pha
(recruiting)favor of a newer, chemically similar analogue (marimastat)
with much improved oral bioavailability.41,42 During clinical
trials, marimastat exhibited modest efficacy in delaying
disease progression; however, significance could not be
established due to dose-limiting toxicity. Patients taking
marimastat experienced significant musculoskeletal pain
and inflammation. As results of these trials were not sta-
tistically significant in regards to either symptomatic pro-
gression or overall survival, development of this drug was
stopped.43
The hydroxamic acid moiety used in these early com-
pounds to chelate the zinc lacks specificity for zinc over
other divalent transition metals. Further, it has the ability to
bind metal ions such as Fe3þ which have several oxidation
states.44 Thus, efforts were undertaken to diversify the
groups chelating the catalytic zinc in order to improve
selectivity for this ion. As crystal structures of MMPs became
available, computational structure-based drug design was
utilized to develop small molecule inhibitors which bound to
the active site and exhibited improved pharmacokinetic
properties. A review by Whittaker et al established a clas-
sification system of small molecule MMPIs based on the
group used to bind the catalytic zinc; these groups are
hydroxamates, carboxylates, thiols, phosphorous-based
zinc binding groups, or others (Table 2). Changing the
chelating moiety from a hydroxamate to practically any-
thing else reduces the potency of the drug greatly, which is
believed to be due to a change in the binding mode and
diminished donor ability. However, studies indicate that the
choice in zinc-binding group can influence MMP isoform
selectivity. This is attributed to slight differences in hydro-
phobic interactions, the pKa of the inhibitor, and ring
sterics.45
CGS 27023A (Novartis, also known as MMI-270) is a small-
molecule inhibitor which targets MMP-2, -8, and -9. An iso-
propyl substituent a to the Zn2þ-chelating hydroxamic acid
moiety confers specificity by binding in the S10 subsite. CGS
27023A also has a bulkier moiety believed to bind within the
shallow, solvent-exposed S20 pocket on the enzyme’s surface
which is believed to further increase specificity.46 Though no
anti-proliferative effect was discernible in preclinicalStudy phase
scites, malignant effusion Cancelled in phase III
er, small cell lung cancer,
ell lung cancer
Cancelled in phase III
lid cancer Cancelled in phase I
ell lung cancer, glioblastoma
prostate cancer
Cancelled in phase III
cer, adenocarcinoma of the
on-small cell lung cancer,
arthritis, rejection of organ
Cancelled in phase III
r periodontal diseases, multiple
ase IV), type II diabetes (phase IV),
rysm (phase II), coronary artery
se II), polycystic ovarian cancer
Approved or ongoing
30 J. Cathcart et al.studies, CGS 27023A did significantly attenuate angiogenesis
andmetastasis while reducing tumor burden in rat models of
breast and endometrial cancer.47 Ultimately, in clinical tri-
als for patients with non-small cell lung carcinoma, this drug
also was terminated due to poorly tolerated joint and mus-
cle pain.39
Several other small-molecule MMPIs made their way to
clinical trials. Prinomastat, an optimized version of CGS
27023A, was tested in clinical trials for use as an anti-
angiogenic.48 Once again, phase III clinical trials were
cancelled before completion due to a lack of efficacy in
patients with late-stage disease. Reportedly however, the
typical musculoskeletal adverse effects associated with
previously tested MMPIs were not an issue.49 Tanomastat
utilizes a carboxylate group to chelate the catalytic zinc ion
and was found to be more selective than the prior experi-
mental compounds. The drug was clinically investigated for
treatment of solid tumors, rheumatoid arthritis, and in
preventing rejection of transplanted organs.50 Although
tanomastat was well-tolerated, once again there was no
significant evidence of improved survival outlook or
decreased rate of progression in cancer patients.48,50
All of the compounds discussed thus far had an auspi-
cious start pre-clinically but ultimately failed to achieve
clinical success. The reasons for this are many. As noted
earlier, there are clear structural similarities in the cata-
lytic domain across the family of MMPs. Thus even the most
selective of the drugs tested failed to achieve sufficient
selectivity to circumvent adverse effects. Compounding the
lack of selectivity is the fact that MMPs have normal func-
tions remodeling the ECM system-wide, hence the muscu-
loskeletal effects observed for the majority of the clinically
tested drugs. Particularly of interest, preclinical testing of
efficacy for all of these compounds focused on models of
early-stage cancers. However, patients were enrolled in all
of the clinical trials without regard to the stage of their
disease. Because MMPs contribute to driving disease pro-
gression, MMPIs may be more successful if used as preven-
tative measures or as early-stage therapeutics.4,25,51,52
Indeed, in a prevention study in mice batimastat reduced
angiogenic islands in a model of pancreatic cancer by 49%.
In an intervention trial using the same mouse model, the
compound reduced tumor burden by 83%. However, bati-
mastat had no effect on regression of large tumors or
invasive carcinoma.53,54 In hindsight, we can now appre-
ciate that the clinical studies may not have been optimally
designed. Considering the role of MMPs in cancer, it is very
likely that MMPIs would be found useful only if trials were
designed similarly to the preclinical approach. In other
words, these drugs may have had better success had they
been tested in patients diagnosed with early stage disease
or provided as a post-operative preventative measure for
those who have had surgical resection of a primary tumor.
The era of pharma’s interest in MMPIs ended quickly and
with little clinical success. For some timeafter the failures of
these early campaigns, the industry largely shied away from
investing in development of MMPIs. But because MMPs have
been implicated in somany diseases, they are too tempting a
target to be given up on completely. More recently, design
and development of MMPIs has focused on development of
compounds with high potency and selectivity for a particular
MMP (instead of a broad-spectrum approach) and/or noveldelivery mechanisms to target only the diseased tissue(s).
Because of the structural and sequence similarity conserved
at the catalytic domains, efforts have shifted to investigating
compounds which confer allosteric inhibition.Monoclonal antibodies as catalytic domain
inhibitors
To date, at least two monoclonal antibodies have been
tested which bind to the catalytic domain, likely blocking
substrate access but without interacting with the catalytic
zinc. DX-2400 is aMMP-14 specific inhibitorwhichbinds to the
catalytic domain with a Ki in the sub-nanomolar range.
55 The
drug, developed by Dyax before Kadmon Corporation ac-
quired the rights, was identified by screening using antibody
phage display technology. MMP-14, which is a membrane-
bound MMP, is overexpressed in most human cancers and is
capable of cleaving the major fibrillar collagens. MMP-14 is
also known to activate pro-MMP-2 and participates in such
physiological processes as angiogenesis, cell invasion, and
metastasis.21 Thus far, preclinical studies of DX-2400 indi-
cate that the antibody is capable of inhibiting all of these
activities but yet has no measurable effect on other MMPs.55
In mouse studies, the drug was observed to significantly
decrease tumor burden and decreased number of
metastases observed in the lung and liver. Further, DX-2400
was effective against HER2-positive xenografts both when
used as a single agent or in combination with paclitaxel. This
marks DX-2400 as an attractive candidate for patients diag-
nosed with the especially hard-to-treat triple-negative
breast cancer.55 To date, clinical trials for this therapeutic
have not yet been initiated.
A murine monoclonal antibody, termed REGA-3G12, has
also been generated by hybridoma technology against the
catalytic domain of human MMP-9 secreted by neutro-
phils.56 This compound is unique because it inhibits MMP-9
without affecting activity of MMP-2, another gelatinase to
which it is closely related and with which it shares high
homology.57 MMP-9 is secreted by most human cancer cells
and can be secreted by infiltrating immune cells (including
macrophages and neutrophils) and contributes to tumor
progression, angiogenesis, and tumor cell invasion. MMP-9
activation can be induced by inflammatory cytokines,
growth factors, and cell/stroma interactions particularly in
the most malignant cells whereas MMP-2 is thought to be
constitutively expressed by many cell types.58,59 Therefore,
a therapeutic which can differentiate between these two
highly similar enzymes may prove very useful.Hemopexin domain inhibitors
Because the hemopexin domain exhibits significantly less
sequence and structural homology compared to the cata-
lytic domain, much research has focused on discovery of
inhibitors which can bind to this region. This domain com-
prises a succession of four structurally similar hemopexin-
like repeats. Each of these repeats appears in the shape of
a blade, forming a propeller-like structure with the blades
oriented in such a way to create a central funnel-like tun-
nel. Each blade is made up of four b-strands; the first three
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whereas the b4 strands bear the least. The tunnel created
by this propeller structure traverses its length and is highly
solvated. As many as four structural ions have been found
to be coordinated within this tunnel and it has been pro-
posed that these ions confer a stabilizing function for the
whole domain.60 The evidence for this is that MMP-9, which
has only a sodium ion, displays a flexible architecture and
considerable deviation from the structure of hemopexin
domains reported for other MMPs.61 The first ion binding
position, which is closest to the linker region connecting
the hemopexin domain to the catalytic domain, is generally
either a sodium or calcium ion. Next typically comes a
chloride ion, followed in the third position by another
cation, frequently calcium. The fourth position is generally
occupied by another anion, which is usually chloride.60
Compounds which bind to the hemopexin domains and
prevent dimerization have been shown to significantly
decrease tumor size, reduce MMP-mediated cell scattering/
invasion, angiogenesis, and tumor metastasis both in vitro
and in animal models.62e65 Small molecule inhibitors which
bind at the hemopexin domain of MMP-14 (a membrane-
type MMP) and MMP-9 have been described. In silico anal-
ysis of the MMP-14 hemopexin domain identified a drug-
gable pocket-like site in the center of the hemopexin
structure. Binding of small molecule compounds in this site
should, in theory, allosterically block dimerization. Subse-
quent docking studies of small-molecule compounds led to
identification of a compound which is selective for MMP-14
compared to MMP-2 and was not cytotoxic and did not
affect catalytic activity (including MMP-14-mediated acti-
vation of MMP-2). This compound was effective in attenu-
ating cancer cell migration and in vivo reduced tumor
volume and caused a fibrotic tumor phenotype (hypothe-
sized to be a result of a decreased ability for the cancer
cells to invade).63 Similar studies have been spearheaded
against MMP-9, in which docking programs were utilized to
map potential ligand binding sites in the hemopexin domain
at the dimerization interface. The compound identified in
that study also yielded one with no proteolytic or cytotoxic
effects but which significantly decreased cancer cell
migration and invasion and, in vivo, significantly decreased
tumor size as well as the number of metastases.64
Similar to the small molecule compounds described
above, small peptides have been used successfully to block
dimer-induced functions of MMPs, including cancer cell
migration, invasion, angiogenesis, and in vivo metastasis.
MMP-14 homodimerizes via the outer strand of blade IV and
also heterodimerizes through the outer strand of blade I
with CD44 in order to induce intracellular cytoskeleton
rearrangements necessary for processing of migration and
invasion machinery, including proteolysis of proMMP-2 by
MMP-14.66,67 On the other hand, MMP-9 homodimerizes via
blade IV to induce cell migration.68 Short peptides that
mimic the sequence of the residues with which the
hemopexin-like domains dimerize were able to reduce
tumorigenic effects in vitro and, in the case of the MMP-14
peptides, in vivo.62,65
Taking another approach, a fusion protein has been
designed which links the ten amino acid sequences of a
MMP-2 selective inhibitory peptide (APP-IP, a b-amyloid
precursor protein) to the N-terminus of TIMP-2. Thismacromolecular protein, which binds with a Ki in the sub-
picomolar range, is designed to interact with both the
active site and the hemopexin-like domain of MMP-2. This
bimodal approach confers increased selectivity for MMP-2
compared to either subunit individually. The binding of
the inhibitor at the catalytic domain blocks catalytic
activity while the interaction with the hemopexin-like
domain prevents binding of endogenous partners that can
promote angiogenesis or cancer cell migration. Selectivity
for MMP-2 was confirmed via fluorometric enzyme activity
assay and indicates that the concentration of APP-IP-TIMP-2
necessary to inhibit MMP-1, MMP-3, MMP-7, MMP-8, MMP-9,
or MMP-14 is over six-fold higher than for MMP-2.69Targeting structural elements to upset the
global architecture
To date, there is a single approved therapeutic which in-
hibits MMPs, albeit it is approved at this time only for peri-
odontal diseases. A chemically modified tetracycline,
doxycycline (Periostat), works to inhibit MMPs via a
mechanism unrelated to its well-characterized antimicro-
bial activities. Though considered broad-spectrum in-
hibitors, chemically modified tetracyclines are most useful
against the collagenases. In the case of doxycycline, the
drug’s lower half is rich in oxygen, making it a potent
chelator of divalent metals.70 Exactly how doxycycline binds
remains enigmatic. However, models indicate that doxycy-
cline is capable of chelating the structural cations coordi-
nated in either the catalytic domain or the hemopexin-like
domain but is likely not capable of chelating the catalytic
zinc.71,72 In the case of MMP-7, doxycycline has been
demonstrated by deuterium exchange mass spectroscopy to
interact with hydrophobic tryptophan residues in the MMP
which are proximal to the structural zinc within the catalytic
domain, thus affecting global conformation of the enzyme
and rendering it inactive.73
As an added bonus, chemically modified tetracyclines
have been shown to inhibit TNF-a and IL-8 production,
thereby targeting the MMP expression pathway and
reducing overall MMP levels.74 The safety, toxicity, and
efficacy profiles of tetracyclines and their derivatives,
including doxycycline, are well known and have been used
as antibiotics safely for years. Further, tetracyclines are
attractive for development as they are natural compounds,
easily isolated, and their toxicity, efficacy, and pharmaco-
kinetic profiles are well described.75 Thus, unsurprisingly,
several clinical trials recruiting or in progress are investi-
gating doxycycline in combination with standard chemo-
therapeutics for use in cancer therapy.Designing targeted drug delivery systems
The majority of current chemotherapeutics target any
dividing cell, system-wide. These non-specific, systemic
effects are what lead to the adverse symptoms typically
associated with cancer treatment such as hair loss or loss of
appetite. Because the early, unsuccessful MMPIs were non-
specific and systemically available, recent research has
32 J. Cathcart et al.begun looking at drug delivery systems which will only be
effective within the tumor environment.
Liposome systems conjugated to a selectivity marker
which encapsulate cytotoxic agents have emerged as an
innovative way to deliver therapeutics specifically to tumor
cells. Liposomes are spherical vesicles composed of a
lamellar phase lipid bilayer with a solvated inner core.
Various compounds may be chemically conjugated to these
systems to stabilize the system, confer selectivity, or
trigger cellular uptake. One recent study demonstrates the
use of a monoclonal antibody, mAb 2C5, which recognizes
cell surface nucleosomes expressed on cancer cells, along
with a MMP-2 cleavable peptide to provide additional
selectivity at the tumor site. The MMP-2 cleavable peptide
also acts to shield a cell-penetrating peptide that enables
entry of the system into the target cell. In this approach,
the cytotoxic effects conferred by the encapsulated drug
cannot be initiated unless MMP-2 first cleaves the linker to
remove the blocker and expose this membrane-penetrating
peptide.76
Similar to liposomes, nanoparticles are another system
which can be modified in order to selectively deliver a
cytotoxic payload to cancer cells. Nanoparticles have been
engineered in such a manner that hydrophilic compounds
can be conjugated to the particle surface and more hydro-
phobic compounds, such as cancer drugs like doxorubicin,
can be incorporated inside the particle. The MMP substrate
peptide PLGVR was conjugated to mesoporous silica nano-
particles to provide selectivity at the MMP-expressing tumor
site. Cellular uptake of these nanoparticles is only initiated
after cleavage of this peptide. Although nanoparticles on
their own can arbitrarily cross any cell membrane, the fact
that the tumor microenvironment is very acidic can be
leveraged to reduce non-specific effects. The loading of
polyanions onto the surface of the particles repels non-
cancer cells and allows the particles to accumulate in
cancerous tissues. Cancer chemotherapeutics loaded into
the core can induce tumor cell death following nanoparticle
uptake. In vitro experiments demonstrate these nano-
particles are taken up by cells expressing MMPs and cyto-
toxic effects are observed following cleavage of the MMP
substrate by cancer cells.77 Like liposomes, nanoparticles
have potential clinical use for selective delivery of chemo-
therapeutics and may attenuate the harsh side effects
typically associated with traditional approaches.
As discussed earlier and reviewed in detail in reference
35, the biggest contributing factor to the failure of the
early MMPIs in the clinic was the system-wide exposure.
For skin dysplasias however, application of a topical
ointment can easily bypass this issue. In many cancers,
natriuretic peptide receptor-A (NPR-A) is overexpressed
and is associated with cancer aggressiveness as well as
increased inflammation (which drives cancer progres-
sion).78 In vivo studies of a mouse model of melanoma in
which mice were treated with an ointment containing a
NPR-A inhibitor demonstrated significantly decreased ac-
tivity and expression levels of MMP-2 and MMP-9.79 Similar
studies have also been completed successfully using an
ointment containing a synthetic retinoid to directly
inhibit MMPs but in a diabetic ulcer model. In this case,
not only did expression and activity of MMP-1, -2, and -9
decrease but the rate of wound healing increased.80e82Conclusions
MMPs remain a viable target for cancer therapeutics.
However, for MMPIs to be clinically successful, they will
need to be highly selective for a particular MMP and able to
accumulate in cancerous tissues without eliciting adverse
systemic effects. Although MMPI programs were initiated
industry-wide in the era following identification of their
role in cancer, the initial trials failed across the board
despite preclinical data indicating that MMPIs have great
potential for therapeutic use. Since these first trials were
initiated, vast amounts of literature have been published
regarding the biochemistry of MMP expression, function,
and their contribution to pathological progression.
Furthermore, post-clinical reviews of how clinical trials
were conducted provide a better understanding of the
timing for which MMPIs will be beneficial. Taking this into
consideration, it is clear that the time is now ripe for the
industry to once again begin investing in MMPI programs.Conflicts of interest
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